Van der Doelen and coworkers have recently carried out an observational cohort study including 13 consecutive mCRPC patients (of whom, 2 previously treated with [177Lu]Lu-PSMA-617), submitted to [225Ac]Ac-PSMA-617 RLT: in all cases PSMA-expression was tested with [68Ga]Ga-PSMA-11 PET/CT and on tumor tissue by histochemical analysis before therapy enrollment [24]. This evidence concerns the gene FOLH1 and neoplasm.